Why It Matters

Colgate-Palmolive Co. is upgrading its lobbying strategy with the addition of Alpine Group Partners LLC, shifting from chemical safety focus to direct FDA and HHS engagement on oral-care regulation and medical research.

The move comes as Congress intensifies scrutiny of personal care ingredients. The Oral Health Products Inclusion Act (H.R. 1219) would expand consumer access to oral care products through tax-advantaged health accounts—a significant revenue opportunity. Meanwhile, Rep. Jan Schakowsky’s Safer Beauty Bill Package threatens to ban 18 chemicals from personal care products.

Colgate’s new team includes former House Energy and Commerce Committee Chairman Gregory Paul Walden, providing direct access to the committee with sole FDA jurisdiction. Competitor Procter & Gamble and the Consumer Healthcare Products Association are already lobbying on similar issues, signaling a critical policy moment for the industry.

By the Numbers

Colgate-Palmolive has spent $5.2 million on lobbying over two decades, previously retaining firms including Baker & Hostetler LLP ($4.58 million), with recent engagements focused on chemical reform and manufacturing.

The new Alpine Group Partners team includes five healthcare specialists: Walden (former Energy and Commerce Chairman), Shayne Gregory Woods (8+ years on Energy and Commerce staff), Colin C. Brainard (11+ years congressional experience), Erin Katzelnick-Wise Mendelsohn (former Health Subcommittee staffer), and Hannah Amalie Schmidt (MPH, 3+ years Hill experience).

Alpine Group has filed over 2,000 lobbying disclosures since 2003 with $153 million in total compensation, representing major healthcare clients.

The Agenda

Colgate is targeting the Oral Health Products Inclusion Act, which would classify over-the-counter oral care products as qualified medical expenses for Health Savings Accounts—potentially expanding consumer access significantly.

The company faces regulatory headwinds from Schakowsky’s chemical ban legislation and FDA restrictions on fluoride supplements, creating pressure to reformulate products. House hearings on domestic manufacturing have highlighted supply chain concerns relevant to Colgate’s operations.

Competitors are already engaged: Procter & Gamble lobbies on oral care access, while CHPA campaigns on ingredient safety and tax-advantaged account expansion.

Broader Context

Congress is reshaping oral care regulation amid significant FDA flux. The agency has moved against fluoride supplements, signaling broader skepticism about core ingredients in Colgate’s products. The Trump administration’s "Make America Healthy Again" agenda drives reassessment of ingredient approvals.

Bipartisan momentum behind H.R. 1219 creates opportunities, while the delayed rollout of the 2022 Cosmetics Regulation Act opens windows for industry input on implementation.

Bottom Line

Colgate’s Alpine Group hire positions the company for high-level engagement during a pivotal regulatory period. With Walden’s Energy and Commerce access and specialized healthcare expertise, Colgate can now compete directly with P&G and industry associations on critical oral care policy. The timing aligns with both regulatory threats and significant revenue opportunities through expanded health account access.

Spot something wrong? Report an issue with this article